Rituximab and Multiple Sclerosis
Clinical Neuropharmacology,  Clinical Article

Goldman JG et al. – Data presented were categorized in 3 groups based on the nature of data presented (radiological, clinical, and immunological data). Both case-control studies and case reports were included, while table classification was in chronological order

  • B lymphocytes seem to have a fundamental role in multiple sclerosis, acting as sensors, coordinators, and regulators of the immune response.
  • Furthermore, they are important in activating T cells and they can mediate tissue injury through diverse mechanisms.
  • Such findings have important therapeutic implications in autoimmune central nervous system diseases in a fashion similar to other autoimmune processes.
  • The best known monoclonal antibody targeting B cells that has been used as a novel therapy for various autoimmune conditions, as well as multiple sclerosis, is rituximab.
  • This review summarizes the available data on the role of B cell in multiple sclerosis and further reports on current knowledge on the B-cell–depleting monoclonal antibody rituximab, its mechanism of action, and its efficacy on multiple sclerosis.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore